Related references
Note: Only part of the references are listed.Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets
Masaki Imai et al.
NATURE (2012)
Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals
Anna Kajaste-Rudnitski et al.
AIDS (2011)
Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with Type 1 diabetes mellitus
G. V. Zuccotti et al.
DIABETIC MEDICINE (2011)
MF59 adjuvant: the best insurance against influenza strain diversity
Derek T. O'Hagan et al.
EXPERT REVIEW OF VACCINES (2011)
Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations
Angelika Banzhoff et al.
HUMAN VACCINES (2011)
Combined, Concurrent, and Sequential Administration of Seasonal Influenza and MF59-Adjuvanted A/H5N1 Vaccines: A Phase II Randomized, Controlled Trial of Immunogenicity and Safety in Healthy Adults
Pio Lopez et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients
Susanna Esposito et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Oil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children
Timo Vesikari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy: A six-month update
Antonio Crucitti et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2011)
Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy
Theodore F. Tsai et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2011)
MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines
Surender Khurana et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis
Federico Alghisi et al.
THORAX (2011)
Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children
Sara Meier et al.
VACCINE (2011)
A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly
Elena Fragapane et al.
CLINICAL AND VACCINE IMMUNOLOGY (2010)
A Phase III, Randomized, Open-Label Study to Assess the Tolerability and Immunogenicity of an H5N1 Influenza Vaccine Administered to Healthy Adults With a 1-, 2-, 3-, or 6-Week Interval Between First and Second Doses
Jiri Beran et al.
CLINICAL THERAPEUTICS (2010)
MF59™ as a vaccine adjuvant: a review of safety and immunogenicity
Hana El Sahly
EXPERT REVIEW OF VACCINES (2010)
Pre-pandemic and pandemic influenza vaccines
Steven Rockman et al.
HUMAN VACCINES (2010)
Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine From Infancy to Adolescence
Timo Vesikari et al.
PEDIATRICS (2010)
Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus
Surender Khurana et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major
Susanna Esposito et al.
VACCINE (2010)
Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis
Steven Black et al.
VACCINE (2010)
Exposure to MF59-adjuvanted influenza vaccines during pregnancy-A retrospective analysis
Theodore Tsai et al.
VACCINE (2010)
MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults
Angelika Banzhoff et al.
PLOS ONE (2009)
Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine
Grazia Galli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels
Grazia Galli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination
T. Vesikari et al.
VACCINE (2009)
MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database
Michele Pellegrini et al.
VACCINE (2009)
Genotypic diversity of H5N1 highly pathogenic avian influenza viruses
Zi-Ming Zhao et al.
JOURNAL OF GENERAL VIROLOGY (2008)
Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans
Lance C. Jennings et al.
LANCET INFECTIOUS DISEASES (2008)
Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1
Iain Stephenson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine:: a randomised controlled trial
Isabel Leroux-Roels et al.
LANCET (2007)
Strategies for mitigating an influenza pandemic
Neil M. Ferguson et al.
NATURE (2006)
Confronting the avian influenza threat: vaccine development for a potential pandemic
I Stephenson et al.
LANCET INFECTIOUS DISEASES (2004)
Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
KG Nicholson et al.
LANCET (2001)